Martin Devenport

Institution:

ONCOIMMUNE, INC.

Email:

Awarded COVID Grants:

SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients

Back to Top